Rosetta Genomics (ROSG) New York State Grants Final Approval for Its miRview(R) Lung Assay

Author: Karlos Darwin

ROSGreported that the New York State Department of Health has given the Company final approval for its miRview(R) lung assay following conditional approval issued in June 2012.
With this final approval, ROSG can continue to offer the miRview(R) lung assay in all 50 U.S. states. New York is the only U.S. state that requires an independent regulatory review process for laboratory-developed tests.
miRview(R) lung is ROSG‘s proprietary microRNA-based assay that can accurately differentiate between the four main subtypes of lung cancer using small amounts of tumor cells.
ROSG develops and commercializes a full range of microRNA-based molecular diagnostics.


ENZ, Enzo Biochem Inc.

ENZ is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards.
ENZ utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. ENZ's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
In June 2004, ENZ filed a lawsuit in the United States District Court for the District of Connecticut against Applera Corporation and its subsidiary Tropix Inc. charging them not only with patent infringement, but also with providing others with unauthorized and prohibited access to the patented products and technologies.
ENZ reported last week that it was awarded $48.6 million after a federal jury said Life Technologies Corp.'s Applera unit infringed a patent over a way to detect genetic sequences and diagnose human diseases such as cancer.
ENZ's attorneys estimate that the addition of the pre-judgment award should add additional recoveries of up to tens of millions of dollars.


FCEL, FuelCell Energy Inc.
** FCEL reported an order from its South Korean partner, POSCO Energy for 121.8 megawatts of fuel cell kits and services to be manufactured at the FCEL production facility in Torrington, Connecticut. The estimated value of the multi-year contract is approximately $181 million.
POSCO Energy, the largest independent power producer in South Korea, is a subsidiary of POSCO, a leading global steel producer.
This is the largest order ever received by FCEL and the fuel cell industry, almost tripling FCEL‘s product backlog and initiating its planned increase in production levels for 2013.

FCEL is a global leader in providing ultra-clean baseload distributed generation to utilities, industrial operations, universities, municipal water treatment facilities, government installations and other customers around the world.

Posted in: Investing